AVBP Q3 2024 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$21M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$866,000

Balance Sheet

Total Assets

$293M

Total Liabilities

$15M

Stockholders' Equity

$277M

Cash & Equivalents

$283M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$17M	-45.0%
Net Income	-$21M	-$14M	-42.8%